Artificial intelligence is driving unprecedented advancements across the entire pharmaceutical value chain—from drug discovery and clinical development to patient-centric care and operational optimization. By leveraging the power of AI, pharmaceutical companies can unlock insights from vast, complex datasets, streamline R&D processes, and expedite the delivery of cutting-edge therapies. This not only accelerates time to market but also paves the way for more personalized, effective treatments and significantly improved patient outcomes. The strategic deployment of AI in the pharmaceutical industry is no longer a future consideration; it is a competitive imperative shaping the industry’s next era of innovation.
That was the focus of a recent digital roundtable hosted by Atreus, the leading provider of interim leaders and experts in Germany and Europe, and a Heidrick & Struggles company. Led by Christian Wagner, director at Atreus, the webinar convened a panel of industry leaders and AI experts to explore both the extraordinary potential and the current limitations of AI in the pharmaceutical sector.
Watch the discussion or read on for highlights on how AI is reshaping the pharma landscape—as well as the strategic challenges that must be navigated to fully realize AI’s promise in this highly regulated and data-intensive field.
AI in Pharma: Insights and Takeaways
The Importance of Aligning AI with Business Objectives
Jack Lampka, a keynote speaker with 27 years of experience in technology and AI, cautioned against the common mistake of starting AI initiatives by focusing on the technology, which often results in a “solution looking for a problem.” Noting that 70% of AI projects fail—often for this very reason—he instead advises companies to start with concrete challenges that need to be addressed in the business. In the pharmaceutical industry, this means decision-makers should first identify specific areas where AI can deliver measurable value—such as optimizing sales strategies or streamlining research and development—and establish clear KPIs to ensure focus and accountability.
Lampka also notes that bringing the business side into the early stages of AI initiatives is essential. Because success hinges not just on the quality of the AI solution, but on whether it is actively used, it’s crucial to involve business stakeholders in setting usage goals and make them co-owners of the AI-driven outcomes. But Lampka emphasizes that adoption will not be automatic. AI leaders should develop a well-thought-out internal marketing strategy to effectively communicate the benefits of their initiatives to stakeholders and ensure solutions are both understood and embraced across the organization.
Corporate Culture’s Role in AI Adoption
Successful AI implementation hinges on fostering a corporate culture that embraces innovation and change. These initiatives require employees to shift how they operate, adopt new tools, and adapt workflows. Without openness to change, even the best AI solutions will falter. Lampka also stresses the importance of addressing employees’ key question: “What’s in it for me?” Clear communication about how AI benefits individual roles is essential to securing buy-in.
To increase buy-in, Lampka suggests that organizations work to promote a data mindset company wide. One way to do so is by creating data literacy programs that demonstrate how AI can improve employees’ daily activities and operations, while helping data scientists understand operational challenges. Engaging enthusiastic employees in AI development in this way can help companies develop advocates, further driving adoption. Executive support is equally crucial; leaders should be actively involved in fostering organizational acceptance of AI solutions.
AI Is a Diverse Ecosystem of Technologies
Lampka emphasizes the importance of distinguishing between different forms of AI, including machine learning (ML), deep learning (DL), and generative AI (gen AI). While ML and DL have been used for years in contexts such as predictive analytics for sales and marketing, gen AI, the “new kid on the block,” excels at creating content such as text, images, and videos. For pharmaceutical companies, understanding these distinctions helps in selecting the right AI technology to meet specific business needs.
Lampka also notes that while generative AI is currently generating buzz, traditional ML and DL have the potential to provide even greater business value. While McKinsey estimates that gen AI could contribute up to $4 trillion annually to the global economy, it’s possible that ML and DL could generate up to four times that amount. Accordingly, Lampka cautioned companies to not let the hype around gen AI overshadow the proven impact of ML and DL, which continue to drive significant value across industries.
AI’s Role in Pharmaceutical Sales and Marketing
In pharmaceutical sales and marketing, AI offers significant opportunities. AI can define customer segments, provide insights into key physicians’ preferences, and estimate patient numbers in regions with strict regulations. For sales teams, AI can recommend next best actions, advising on which physicians to target, which channels to use, and what content to deliver. By analyzing vast customer data, AI uncovers insights that enhance marketing strategies and improve return on investment (ROI).
Additionally, AI optimizes resource allocation, identifying the most effective sales channels and marketing strategies. It also enables customized content creation, including avatar training videos in multiple languages, helping pharmaceutical companies scale their marketing efforts efficiently.
Navigating Compliance Issues Around AI
AI strategy expert Dr. Marlon Rück stresses the importance of and challenges around regulatory compliance when integrating AI into the pharmaceutical industry. Given the high stakes, particularly around patient safety and treatment efficacy, AI systems must be thoroughly tested at all levels to ensure safe and reliable implementation.
Rück also highlights that compliance must be considered from the very early stages of AI planning. Organizations should prioritize transparency and closely collaborate with authorities to ensure their AI solutions meet all regulatory standards. By embedding these practices into AI development, companies can mitigate risks and ensure successful, compliant AI integration that delivers real value.
Balancing AI Capabilities with Human Oversight
AI consultant and interim leader Dr. Maximilian Pinker cautions against overestimating AI’s capabilities, especially in decision-making processes that require human judgment. He emphasizes that while AI excels at processing data and recognizing patterns, it cannot replace human oversight in critical areas like compliance and accuracy. In the pharmaceutical industry, AI systems lack the predictability of traditional systems, making it difficult to validate AI for good manufacturing practices (GMP), as the same input may produce different results over time.
Pinker acknowledges that AI can enhance efficiency, speeding up content creation and handling parallel processes that would otherwise be costly. However, the limitations, particularly around validation and regulatory compliance, remain a challenge. He advises a balanced approach—leveraging AI’s strengths while ensuring human oversight to meet compliance needs. Staying informed and pragmatic as AI technology evolves is crucial to navigating both its potential and limitations.
Operational Efficiency Gains through AI
AI offers significant opportunities to streamline production, from planning and optimization to maintenance scheduling. Automating routine tasks and using AI-driven analytics enables better resource allocation, quicker market responses, and a stronger competitive edge. Furthermore, AI can optimize production planning, process workflows, procurement, and energy consumption, ensuring smoother operations and timely availability of materials.
Rück also highlights how AI-driven knowledge management can prevent knowledge silos, while automating manual tasks like document writing speeds up processes. This combination of automation and optimization can help companies increase efficiency, maintain compliance, and reduce costs throughout the production cycle.
AI’s Impact on Drug Development
Rück highlights AI’s transformative potential across the drug development cycle, from discovery to clinical trials. AI can streamline the discovery process by predicting the properties of proteins and drugs, helping pharmaceutical companies identify promising candidates faster and allocate resources more efficiently.
On the clinical side, AI can predict patient profiles for trial site selection, forecast adverse effects, and generate synthetic patient data for virtual trials. By reducing development time, companies can improve time-to-market and launch drugs faster—gaining more time under patent protection and increasing revenue potential during exclusivity.
The Bottom Line
Even as adoption rapidly grows, companies are still only scratching the surface of AI’s use cases in the pharmaceutical industry. By focusing on strategic alignment, development of a company-wide data mindset, and regulatory compliance, life science leaders can unlock the enormous potential of AI to improve patients’ lives and drive business success.
Need help with your AI strategies and implementation? Reach out today to learn how our expert talent solutions can accelerate your critical AI initiatives.
GET THE SKILLS YOU NEED
Thousands of independent consultants, subject matter experts, project managers, and interim executives are ready to help address your biggest business opportunities.
